Cost-effective sourcing of 99% pure Lemborexant CAS 1369764-02-2 raw material
14 Inquiries
1369764-02-2
Pharmaceutical Grade
99%
shanghai
1kg/bag;25kg/Cardboard Drum
2026-08-28
Estradiol,Progesterone,GS441524,4-Butylresorcinol,DeoxyArbutin,Coenzyme Q10
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceLemborexant (E-2006) is a dual antagonist of the orexin OX1 and OX2 receptors which is under development for treatment of insomnia.
Lemborexant is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III.|Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to "switch-off" wake-promoting circuits. Whereas historically popular pharmacologic treatments for insomnia (e.g. [zopiclone], [zolpidem], benzodiazepines) focus on enhancing sleep drive via modulation of GABA and melatonin receptors, lemborexant and other orexin antagonists (e.g. [suvorexant]) act to counteract inappropriate wakefulness. This novel mechanism of action offers potential advantages over classic hypnotic agents, including a more favorable adverse effect profile and potentially greater efficacy, and may signal the beginning of a new wave of treatment options for patients suffering from insomnia.|Lemborexant is an orexin receptor antagonist used for the treatment of insomnia and sleep disorders. Lemborexant therapy is associated with rare occurrence of transient serum enzyme elevations, but has not been implicated in cases of clinically apparent liver injury.Basic Info-
Product Name:
(1R,2S)-2-[[(2,4-Dimethyl-5-pyrimidinyl)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)cyclopropanecarboxamide
Other Name:Cyclopropanecarboxamide,2-[[(2,4-dimethyl-5-pyrimidinyl)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)-,(1R,2S)-;(1R,2S)-2-[[(2,4-Dimethyl-5-pyrimidinyl)oxy]methyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)cyclopropanecarboxamide;Lemborexant;E 2006;Dayvigo
CAS No.:1369764-02-2
Molecular Formula:C22H20F2N4O2
InChIKeys:InChIKey=MUGXRYIUWFITCP-PGRDOPGGSA-N
Molecular Weight:410.4166064
Exact Mass:410.42
UNII:0K5743G68X
DEA Code Number:2245
Categories:
Characteristics-
PSA:
77.00000
XLogP3:3.16
Density:1.347±0.06 g/cm3(Predicted)
Boiling Point:596.1±50.0 °C(Predicted)
Flash Point:314.3±30.1 °C
Refractive Index:1.619
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Estradiol,Progesterone,GS441524,4-Butylresorcinol,DeoxyArbutin,Coenzyme Q10
-
Location:
XINYUAN DADUHUI PHASE 1, NO.258 TAOYUAN NORTH ROAD, LIANHU DISTRICT, XI 'AN , SHAANXI CHINA
-
Payment Terms:
TT against copy of documents,100% TT in advance
-
Average lead Time:
30
-
Total Annual Revenue:
$2.5 million-$5 million
-
Total Employees:
11-50
-
Year of Establishment:
2023
-
-
Inquiry History14 Inquiries
Country Product Purchase Quantity Date Posted
Italy
Lemborexant
1 G Jun 10, 2026
Italy
Lemborexant
1 G May 3, 2026
Paraguay
Lemborexant
20 G Aug 25, 2026
France
Lemborexant
1 G Aug 4, 2026
Hungary
Lemborexant
10 G Mar 5, 2026
Pakistan
Hira
50 G Sep 29, 2025
India
Lemborexant 98℅
10 G Apr 25, 2024
Paraguay
Lemborexant API
2 KG Aug 25, 2026
France
Lemborexant
1 G Aug 5, 2026
United States
Lemborexant
1 G Jul 27, 2026
United States
Lemborexant
1 KG Apr 25, 2026
Hungary
Lemborexant
1 G Apr 12, 2026
China
LEMBOREXANT
5 G Sep 7, 2025
United States
Dihexa, KY19382, WAY-262611, WAY-316606, 7,8-Dihydroxyflavone, Lemborexant
1 G Aug 19, 2026 Post an enquiry for this product